Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
← catalyst calendarSponsored by United Therapeutics (industry) · UTHR — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
314actual
Sites
42
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-11 | actual | When the study began enrolling |
| Primary completion | 2026-03-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-29 | actual | The whole study's end, after follow-up |
| First posted | 2023-03-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Interstitial Lung Disease
- Pulmonary Hypertension
Intervention
- Procedure: Right heart catheterization (RHC)
Primary outcome
what the primary-completion date above is the date OFPercentage of patients with PH as indicated by RHC
measured Through study completion, approximately 3 weeks.
Publications
- PMID 41806275 — linked by the registry
- PMID 40711711 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · UTHR's whole pipeline · Catalyst calendar · Every registered study · What changed